---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-23-000084"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:20:28.902571+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Praxis reports Q1 net loss $37.5M; PRAX-628 Phase 1 positive, cash runway into Q2 2024

## Summary
- Q1 net loss $37.5M ($0.65 per share); cash & investments $85.8M as of March 31, 2023, funding operations into Q2 2024.
- PRAX-628 Phase 1 well-tolerated; PK supports once-daily dosing; concentrations >15-fold MES EC50, indicating potential best-in-class efficacy for focal epilepsy.
- Ulixacaltamide End-of-Phase 2 FDA meeting scheduled June 2023; Phase 3 program in essential tremor planned for H2 2023.
- PRAX-562 EMBOLD study topline results expected Q4 2023; PRAX-222 EMBRAVE topline results expected H2 2023.
- R&D expenses decreased to $25.5M from $52.7M YoY; G&A expenses decreased to $13.3M from $16.2M.

## SEC filing metadata
- accession: 0001689548-23-000084
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954823000084/0001689548-23-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954823000084/prax-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-23-000084
- JSON: https://secwatch.observer/filing/0001689548-23-000084.json
- Plain text: https://secwatch.observer/filing/0001689548-23-000084.txt

## Key facts
- Earnings Releases
  Praxis Precision Medicines, Inc. reported the three months ended March 31, 2023 results: revenue $0.7 million.
  - Period: the three months ended March 31, 2023
  - Revenue: $0.7 million
  - Result: reported results
  source text: Praxis recognized $0.7 million in collaboration revenue during the three months ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689548/000168954823000084/0001689548-23-000084-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.